|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2005-6-10
|
|
pubmed:abstractText |
Intravesical bacillus Calmette-Guerin (BCG) therapy is the principal treatment for high risk, noninvasive urothelial carcinoma and carcinoma in situ of the bladder. However, up to 40% of patients fail to respond to this treatment. In this study the potential for inhibition of PGE2 production by BCG treated dendritic cells (DCs) was studied in the context of preferential polarization of the immune response toward a cancer clearing T-helper type 1 immune response.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0022-5347
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
174
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
332-7; discussion 337
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15947685-Adjuvants, Immunologic,
pubmed-meshheading:15947685-Animals,
pubmed-meshheading:15947685-BCG Vaccine,
pubmed-meshheading:15947685-Cyclooxygenase Inhibitors,
pubmed-meshheading:15947685-Dendritic Cells,
pubmed-meshheading:15947685-Dinoprostone,
pubmed-meshheading:15947685-Drug Synergism,
pubmed-meshheading:15947685-Female,
pubmed-meshheading:15947685-Immunotherapy,
pubmed-meshheading:15947685-Interleukins,
pubmed-meshheading:15947685-Mice,
pubmed-meshheading:15947685-Urinary Bladder Neoplasms
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Cyclooxygenase-2 inhibition: a potential mechanism for increasing the efficacy of bacillus calmette-guerin immunotherapy for bladder cancer.
|
|
pubmed:affiliation |
Department of Surgery/Northern Institute for Cancer Research, Medical School, University of Newcastle, Newcastle-Upon-Tyne, United Kingdom. s.j.dovedi@ncl.ac.uk
|
|
pubmed:publicationType |
Journal Article
|
